EUCTR2006-000138-11-DE进行中（未招募）不适用
A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Clinical symptoms consistent with IPF, including the insidious onset of otherwise unexplained dyspnea on exertion, of more or equal to 3 months duration
- •2. Diagnosis of IPF, defined as first instance in which a patient was informed of having IPF, within 48 months of randomization
- •3. Age 40 through 80 years, inclusive
- •4. High-resolution computed tomographic (HRCT) scan showing a pattern of disease consistent with a confident (definite) radiographic diagnosis of usual interstitial pneumonia (UIP)/IPF. For patients with surgical lung biopsy showing definite or probable UIP, the HRCT criterion of probable (UIP)/IPF is sufficient.
- •5. For patients aged <50 years: open or video-assisted thoracoscopic (VATS) lung biopsy showing definite or probable UIP within 48 months of randomization. In addition, there are no features supporting an alternative diagnosis on transbronchial biopsy or bronchoalveolar lavage (BAL), if performed
- •6. For patients aged more than or equal to 50 years: At least one of the following diagnostic findings, as well as the absence of any features on specimens resulting from any of these procedures that support an alternative diagnosis, within 48 months of randomization.
- •a. Open or VATS lung biopsy showing definite or probable UIP.
- •b. Transbronchial biopsy showing no features to support an alternative diagnosis. These alternative diagnoses include but are not limited to granulomatous disease, sarcoidosis, and hypersensitivity pneumonitis.
- •c. BAL showing no features to support an alternative diagnosis
- •7. Percent predicted FVC =50% at the screen visit and Day 1 (before randomisation). The change in FVC (measured in liters) between the Screen Visit and Day 1 must be =10% relative difference
- •8. Hemoglobin (Hb)-corrected carbon monoxide diffusing capacity/carbon monoxide transfer capacity (DLco) =35% of predicted value at the Screen Visit only
- •9. Either FVC of Hb-corrected DLco =90% of predicted value at the Screen Visit.
- •10. No evidence of improvement in measures of IPF disease severity over the preceding year
- •11. Distance walked more or equal to 150 meters (492 feet) with O2 saturation more or equal to 83% on less or equal to 6 L/min of O2 during the 6-Minute Walk Test (6MWT) oxygen titration procedure performed during screening
- •12. Able to understand and sign a written informed consent form
- •13. Able to understand the importance of adherence to study treatment and the study protocol, including the concomitant medication restrictions throughout the Study Period
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Not suitable for enrolment or unlikely to comply with the requirements of this study in the opinion of the investigator
- •2.Premature withdrawal from randomized IPF clinical trial in the previous 2 years for any reason other than Sponsor decision or current participation in a clinical drug trial
- •3.FEV in the first second (FEV1)/FVC ratio <0.7 after administration of bronchodilator at the screen visit and day 1 before randomisation
- •4.Bronchodilator response defined by absolute increase of =12% and an increase of 200 mL in the predicted FEV1 or FVC or both after bronchodilator use compared to the values before bronchodilator at the screen visit and day 1 before randomisation
- •5. RV >120% of predicted (before administration of bronchodilator)
- •6.History of clinically significant environmental exposure known to cause PF (including drugs, asbestos, beryllium, radiation, domestic birds)
- •7.Known explanation for interstitial lung disease
- •8.Diagnosis of any connective tissue disease including scleroderma, systemic lupus erythematosus, and rheumatoid arthritis
- •9.Clinical evidence of active infection including bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis
- •10.In the clinical opinion of the investigator the patient is expected to need and be eligible for a lung transplant within 72 weeks after randomisation
- •11.Unable to undergo pulmonary function testing which includes meeting the following reproducibility standards: At screening the 2 highest acceptable FVC values must be within 0.10 liter; at day 2 the 2 highest acceptable FVC values must be within 0.10 liter; at screening, 2 of the 3 acceptable DLco values must be within 2 units (for TLco, within 0.67 SI units of each other)
- •12.History of malignancy likely to result in death or significant disability or likely to require significant medical or surgical intervention within the next 2 years. This does not include minor surgical procedures for localized carcinoma (eg basal cell carcinoma)
- •13.Any condition other than IPF which in the opinion of the investigator is likely to result in the death of the patient within the next 2 years
- •14.History of advanced cirrhosis or clinically significant liver disease
- •15.History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months including the following: a.Myocardial infarction, unstable angina pectoris, coronary artery bypass surgery, or coronary angioplasty b.congestive heart failure requiring hospitalization c.Uncontrolled arrhythmias d.Asthma or chronic bronchitis requiring hospitalization in the last 6 months
- •16.Any condition which in the opinion of the investigator might be significantly exacerbated by the known side effects associated with the administration of pirfenidone
- •17.Poorly controlled diabetes (glycosolated hemoglobin [HbA1C] >10)
- •18.Pregnancy or lactation. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective methods of contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of the study. If abstinence is not practiced, then one of the two methods of birth control should be an oral contraceptive (e.g oral contraception and a spermicide).
- •19.History of alcohol or substance abuse in the past 2 years
- •20.History of any condition or habit associated with altered consciousness and a risk of aspiration in the past
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisMedDRA version: 20.0 Level: PT Classification code 10072579 Term: Granulomatosis with polyangiitis System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: PT Classification code 10063344 Term: Microscopic polyangiitis System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.1 Level: PT Classification code 10050894 Term: Anti-neutrophil cytoplasmic antibody positive vasculitis System Organ Class: 10021428 - Immune system disordersEUCTR2016-001121-14-CZChemoCentryx, Inc.300
进行中（未招募）
1 期
A study to determinate the safety and efficacy of LY3471851 in Adult Patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2019-003323-38-HUEli Lilly & Company280
进行中（未招募）
1 期
A study to determinate the safety and efficacy of LY3471851 in Adult Patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2019-003323-38-PLEli Lilly & Company280
进行中（未招募）
不适用
A Study Investigating the Efficacy and Safety of ABT-494 given with Methotrexate in Subjects with Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone.Rheumatoid Arthritis (RA)MedDRA version: 17.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-003984-72-ESAbbVie Inc.270
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of PirfenidonePatients with Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 17.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-000564-14-GBInterMune International AG.122